Crinetics Pharmaceuticals (CRNX) 10-K2021 FY Annual report

Filed: 30 Mar 22, 4:12pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AmideBio, Amolyt, Amryt, anesthesiologist, anesthesiology, antitrust, appoint, appraised, ASCIL, Aug, automated, basal, Beckwith, Bedrosian, beneficiary, Biopharm, biosimilar, BridgeBio, calcium, Camille, chain, Chile, Cipla, CLA, clamp, clarification, Coelho, Colombia, Colorado, Commissioner, conference, confined, constellation, constitutionality, counterparty, customer, depositary, deprioritized, designee, DexTech, discretionary, dismissed, dispute, Donetsk, downturn, draft, economy, Egypt, epidemic, escalating, euglycemic, Eurasia, exacerbate, explicit, FD, formation, Frazier, freestanding, gene, GILTI, Gvoke, HHM, humoral, hyperactive, hypercalcemia, HypoPen, Immunwork, infusion, instructed, instrument, invasion, Kabuki, Kagaku, Kenkyusho, lag, licensee, Luhansk, Malaysia, matching, migrated, military, mimicking, Munchen, mutation, mutually, NaN, nonrefundable, nurse, organizational, PATHFNDR, paused, Peru, phosphate, PHPT, PTH, PTHLH, PTHrP, reabsorption, reconsider, reconsideration, recoverability, recoverable, renal, resorption, Russia, Russian, SA, safest, Sanwa, satisfactorily, seat, situation, skeletal, Sosei, specialist, stake, subordinated, Symptomatic, territory, Thailand, Turner, unconsolidated, underperformance, underwent, underwritten, undistributed, unemployment, universal, unlimited, unnecessary, unstable, upfront, upgrade, vaccine, VIE, Vietnam, Viewpoint, Virginia, Vivaldi, Wiedemann, Zegalogue

Removed: absent, anti, ASC, attack, CHI, Codification, cognizant, comment, comprising, confirming, constitute, converted, customary, degradation, dictate, Dumping, effected, Enesi, EpicentRx, evidentiary, extending, favoring, FDASIA, feature, fraction, gastric, grey, hyperinsulinemic, inseverable, invent, inventor, Judge, Kaldor, lapsed, Linkbase, malate, maximize, Merck, MidaTech, mimic, Northern, par, partnering, pathway, PLC, prosecuted, qualifying, receivable, recycled, redemption, reissuance, rental, repealed, repealing, retroactive, rulemaking, scheduled, Schema, shared, split, Stephen, sunitinib, Taxonomy, trafficked, transitioned, Trump, undergone, vehicle, white, withdrawn, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CRNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Crinetics Pharmaceuticals, Inc. (the “Company”) hereby certifies, to his knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Marc J.S. Wilson

Marc J.S. Wilson

Chief Financial Officer

Date: March 30, 2022

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.